Logo image of NOTV

INOTIV INC (NOTV) Stock Fundamental Analysis

NASDAQ:NOTV - Nasdaq - US45783Q1004 - Common Stock - Currency: USD

2.43  -0.12 (-4.71%)

After market: 2.42 -0.01 (-0.41%)

Fundamental Rating

2

NOTV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. NOTV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NOTV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NOTV has reported negative net income.
NOTV had a negative operating cash flow in the past year.
NOTV had negative earnings in 4 of the past 5 years.
In multiple years NOTV reported negative operating cash flow during the last 5 years.
NOTV Yearly Net Income VS EBIT VS OCF VS FCFNOTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of NOTV (-11.42%) is comparable to the rest of the industry.
With a Return On Equity value of -55.47%, NOTV is not doing good in the industry: 69.09% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -11.42%
ROE -55.47%
ROIC N/A
ROA(3y)-20.38%
ROA(5y)-13.08%
ROE(3y)-65.39%
ROE(5y)-49.53%
ROIC(3y)N/A
ROIC(5y)N/A
NOTV Yearly ROA, ROE, ROICNOTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

NOTV has a Gross Margin of 21.87%. This is in the lower half of the industry: NOTV underperforms 78.18% of its industry peers.
In the last couple of years the Gross Margin of NOTV has declined.
NOTV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.4%
GM growth 5Y-6.74%
NOTV Yearly Profit, Operating, Gross MarginsNOTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

NOTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NOTV has more shares outstanding
The number of shares outstanding for NOTV has been increased compared to 5 years ago.
The debt/assets ratio for NOTV is higher compared to a year ago.
NOTV Yearly Shares OutstandingNOTV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
NOTV Yearly Total Debt VS Total AssetsNOTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

NOTV has an Altman-Z score of -0.53. This is a bad value and indicates that NOTV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.53, NOTV is not doing good in the industry: 78.18% of the companies in the same industry are doing better.
NOTV has a Debt/Equity ratio of 2.50. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.50, NOTV is doing worse than 85.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.5
Debt/FCF N/A
Altman-Z -0.53
ROIC/WACCN/A
WACC8.94%
NOTV Yearly LT Debt VS Equity VS FCFNOTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.50 indicates that NOTV should not have too much problems paying its short term obligations.
NOTV has a worse Current ratio (1.50) than 72.73% of its industry peers.
NOTV has a Quick Ratio of 1.18. This is a normal value and indicates that NOTV is financially healthy and should not expect problems in meeting its short term obligations.
NOTV has a Quick ratio of 1.18. This is in the lower half of the industry: NOTV underperforms 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.18
NOTV Yearly Current Assets VS Current LiabilitesNOTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

NOTV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.16%.
NOTV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.09%.
NOTV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 62.28% yearly.
EPS 1Y (TTM)-15.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.34%
Revenue 1Y (TTM)-13.09%
Revenue growth 3Y76.27%
Revenue growth 5Y62.28%
Sales Q2Q%4.44%

3.2 Future

Based on estimates for the next years, NOTV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.56% on average per year.
Based on estimates for the next years, NOTV will show a quite strong growth in Revenue. The Revenue will grow by 14.23% on average per year.
EPS Next Y40.72%
EPS Next 2Y25.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.43%
Revenue Next 2Y5.83%
Revenue Next 3Y17.67%
Revenue Next 5Y14.23%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NOTV Yearly Revenue VS EstimatesNOTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NOTV Yearly EPS VS EstimatesNOTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NOTV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NOTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NOTV Price Earnings VS Forward Price EarningsNOTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as NOTV.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 130.56
NOTV Per share dataNOTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

NOTV's earnings are expected to grow with 25.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.56%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NOTV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOTIV INC

NASDAQ:NOTV (5/28/2025, 8:00:02 PM)

After market: 2.42 -0.01 (-0.41%)

2.43

-0.12 (-4.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06
Inst Owners29.9%
Inst Owner Change-18.32%
Ins Owners7.66%
Ins Owner Change22.87%
Market Cap83.47M
Analysts80
Price Target5.61 (130.86%)
Short Float %8.64%
Short Ratio3.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.4%
Min EPS beat(2)-5.26%
Max EPS beat(2)32.07%
EPS beat(4)2
Avg EPS beat(4)7.69%
Min EPS beat(4)-17.41%
Max EPS beat(4)32.07%
EPS beat(8)4
Avg EPS beat(8)-2.5%
EPS beat(12)7
Avg EPS beat(12)12.11%
EPS beat(16)9
Avg EPS beat(16)89.74%
Revenue beat(2)0
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-3.54%
Max Revenue beat(2)-1.67%
Revenue beat(4)1
Avg Revenue beat(4)-2.96%
Min Revenue beat(4)-15.95%
Max Revenue beat(4)9.34%
Revenue beat(8)2
Avg Revenue beat(8)-2.6%
Revenue beat(12)5
Avg Revenue beat(12)0.66%
Revenue beat(16)9
Avg Revenue beat(16)3.12%
PT rev (1m)-10.81%
PT rev (3m)-13.16%
EPS NQ rev (1m)-9.57%
EPS NQ rev (3m)-9.57%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.68%
Revenue NQ rev (3m)-1.15%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB N/A
EV/EBITDA 130.56
EPS(TTM)-3.19
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS13.99
BVpS4.59
TBVpS-5.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.42%
ROE -55.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.87%
FCFM N/A
ROA(3y)-20.38%
ROA(5y)-13.08%
ROE(3y)-65.39%
ROE(5y)-49.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.4%
GM growth 5Y-6.74%
F-Score2
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 2.5
Debt/FCF N/A
Debt/EBITDA 109.52
Cap/Depr 34.64%
Cap/Sales 4.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.18
Altman-Z -0.53
F-Score2
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)54.31%
Cap/Depr(5y)102.83%
Cap/Sales(3y)5.33%
Cap/Sales(5y)8.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.34%
EPS Next Y40.72%
EPS Next 2Y25.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.09%
Revenue growth 3Y76.27%
Revenue growth 5Y62.28%
Sales Q2Q%4.44%
Revenue Next Year6.43%
Revenue Next 2Y5.83%
Revenue Next 3Y17.67%
Revenue Next 5Y14.23%
EBIT growth 1Y-6155.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year454.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-544.67%
OCF growth 3YN/A
OCF growth 5YN/A